UBS Group AG
- SEC CIK
- 0001610520
- Latest filing
- Aug 13, 2026
APVO holding history
Aptevo Therapeutics Inc. in every 13F filed by UBS Group AG, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
APVO overviewAll 13F holders of APVOFull Q2 2026 holdings
- Shares (Q2 2026)
- 730
- Value
- $3.24K
- % of portfolio
- <0.1%
- Quarters held
- 14
- Since Q2 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2026 | 730 | $3.24K | <0.1% | −2,715−78.8% | Reduced | Holders |
| Q1 2026 | 3,445 | $14.7K | <0.1% | +3,275+1,926.5% | Added | Holders |
| Q4 2025 | 170 | $1.60K | <0.1% | −145−46.1% | ReducedConverted for a 1-for-18 split | Holders |
| Q3 2025 | 5,673 | $8.23K | <0.1% | +5,673 | New | Holders |
| Q1 2025 | 0 | $0 | 0.0% | −783−100.0% | Sold out | Holders |
| Q4 2024 | 783 | $3.38K | <0.1% | +782+78,200.0% | Added | Holders |
| Q3 2024 | 1 | $0 | 0.0% | −115,909−100.0% | Reduced | Holders |
| Q2 2024 | 115,910 | $35.5K | <0.1% | +115,910 | New | Holders |
| Q1 2024 | 0 | $0 | 0.0% | −5−100.0% | Sold out | Holders |
| Q4 2023 | 5 | $1 | <0.1% | −80−94.1% | Reduced | Holders |
| Q3 2023 | 85 | $28 | <0.1% | +85 | New | Holders |
| Q1 2023 | 0 | $0 | 0.0% | −1,430−100.0% | Sold out | Holders |
| Q4 2022 | 1,430 | $3.32K | <0.1% | +1,000+232.6% | Added | Holders |
| Q3 2022 | 430 | $1.00K | <0.1% | −677−61.2% | Reduced | Holders |
| Q2 2022 | 1,107 | $4.00K | <0.1% | +1,107 | New | Holders |
| Q1 2022 | 0 | $0 | 0.0% | −3,212−100.0% | Sold out | Holders |
| Q4 2021 | 3,212 | $25.0K | <0.1% | +3,212 | New | Holders |
| Q3 2021 | 0 | $0 | 0.0% | −1,821−100.0% | Sold out | Holders |
| Q2 2021 | 1,821 | $41.0K | <0.1% | +1,821 | New | Holders |